<div id="readability-page-1"><p>McAdam LLC decreased its holdings in  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 76.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 516 shares of the pharmaceutical company's stock after selling 1,679 shares during the period. McAdam LLC's holdings in Vertex Pharmaceuticals were worth $250,000 at the end of the most recent quarter.</p><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Activest Wealth Management acquired a new stake in shares of  Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000.  Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of  Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares during the last quarter.  Mascagni Wealth Management Inc. acquired a new stake in shares of  Vertex Pharmaceuticals during the 4th quarter worth approximately $31,000.  Flaharty Asset Management LLC acquired a new stake in shares of  Vertex Pharmaceuticals during the 1st quarter worth approximately $32,000.  Finally, Mpwm Advisory Solutions LLC acquired a new stake in shares of  Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. 90.96% of the stock is currently owned by institutional investors and hedge funds. </p><div><p><span></span><span>Get <strong>Vertex Pharmaceuticals</strong> alerts:</span></p></div><h2>Insider Activity at Vertex Pharmaceuticals</h2><p>In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own  0.20% of the company's stock. </p><h2>Vertex Pharmaceuticals Price Performance</h2><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p>Shares of VRTX opened at $397.37 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The stock has a market cap of $101.88 billion, a PE ratio of 28.40 and a beta of 0.44. The firm has a fifty day moving average price of $423.87 and a 200 day moving average price of $454.15. </p><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same period in the prior year, the company earned ($12.83) earnings per share. The business's revenue was up 11.3% compared to the same quarter last year.  Vertex Pharmaceuticals has set its FY 2025 guidance at  EPS. As a group, equities analysts expect that  Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li></ul><p>A number of analysts have recently issued reports on VRTX shares. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a &#34;market perform&#34; rating for the company. Truist Financial  set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. JPMorgan Chase &amp; Co. lifted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, July 14th. BMO Capital Markets  set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, August 5th. Finally, Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, May 23rd. One research analyst  has rated the stock with a Strong Buy rating, fourteen have assigned  a Buy rating and thirteen have issued  a Hold rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $496.05.</p><p><b>View Our Latest Report on Vertex Pharmaceuticals</b></p><h2>Vertex Pharmaceuticals Company Profile</h2> (Free Report)<p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Vertex Pharmaceuticals</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li><li>NYSE Stocks Give Investors a Variety of Quality Options </li><li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRTX

<p>McAdam LLC reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 76.5% in Q1, holding 516 shares valued at $250,000. Other institutional investors also adjusted their positions. Director Bruce I. Sachs purchased 5,000 shares at $389.68 each, increasing his ownership by 12.5%. Vertex's stock opened at $397.37, with a market cap of $101.88 billion and a PE ratio of 28.40. The company reported $4.52 EPS for the last quarter, exceeding estimates, and has set a FY 2025 EPS guidance. Analysts have mixed ratings on the stock, with a consensus target price of $496.05.</p>

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by McAdam LLC